Toward a Gene Therapy for Dominant Disease: Validation of an RNA Interference-Based Mutation-Independent Approach
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The intragenic heterogeneity encountered in many dominant disease-causing genes represents a significant challenge with respect to development of economically viable therapeutics. For example, 25% of autosomal dominant retinitis pigmentosa is caused by over 100 different mutations within the gene encoding rhodopsin, each of which could require a unique gene therapy. We describe here an RNA interference (RNAi)-based mutation-independent approach, targeting as an example murine rhodopsin. Native transcripts are suppressed by a single RNAi molecular species, whereas transcripts from replacement genes engineered at degenerate third-codon wobble positions are resistant to suppression. We demonstrate suppression of murine rhodopsin transcript by up to 90% with full concomitant expression of replacement transcript and establish the validity of this approach in cell culture, retinal explants, and mouse liver in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Retinopathy induced in mice by targeted disruption of the rhodopsin gene
Humphries, M. M., Rancourt, D., Farrar, G. J., Kenna, P., Hazel, M., Bush, R. A., Sieving, P. A., Sheils, D. M., Creighton, P., Erven, A., et al. (1997) · Nature Genetics · doi:10.1038/ng0297-216 · Cited by 529 · cited 1×
“Indeed it has already been shown that rho mice with approximately 50% of normal rhodopsin levels appear to have near normal histology and ERG activity [31].”
BackgroundSelf-citationOlsson, J. E., Gordon, J. W., Pawlyk, B. S., Roof, D., Hayes, A., Molday, R. S., Mukai, S., Cowley, G. S., Berson, E. L., & Dryja, T. P. (1992) · Neuron · doi:10.1016/0896-6273(92)90236-7 · Cited by 455 · cited 1×
“In support of this hypothesis, a correlation between the severity of disease and the level of expression of mutant rhodopsin transcript has been observed for P23H [27] and P347S rhodopsin mutations [28], suggesting that reduction in levels of mutant rhodopsin may lead to less severe retinal degeneration.”
BackgroundMartinez, L. A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchénio, T., Lozano, G., & Harel-Bellan, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222406899 · Cited by 210 · cited 2×
“However, since siRNA allele specificity can be difficult to achieve [4,15,16] and because in many cases the cost of developing individual therapeutics for each mutation would be prohibitive, the use of mutation-independent methods outlined here will greatly facilitate development of therapies for dominant heterogeneou…”
Background
Cited by
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
“EGFP, Tnf Mouse—reporter IV, IP–DOTAP liposomes Yes No [92] 2003 Luc, EGFP, Gapdh Mouse—reporter IM–electroporation No No [167] 2004 EGFP Mouse—reporter IM–electroporation No No [171] 2005 EGFP Mouse—reporter Cardiac sonoporation No No [173] 2005 EGFP Mouse—reporter IP–virosomes No No [145] 2006 Abcb1a (Mdr1a/1b) Mous…”
BackgroundThe spectrum of ocular phenotypes caused by mutations in the BEST1 gene
Boon, C. J. F., Klevering, B. J., Leroy, B. P., Hoyng, C. B., Keunen, J. E. E., & den Hollander, A. I. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.04.002 · Cited by 348
Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector
Cideciyan, A. V., Sudharsan, R., Dufour, V. L., Massengill, M. T., Iwabe, S., Swider, M., Lisi, B., Sumaroka, A., Marinho, L. F., Appelbaum, T., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805055115 · Cited by 147
Gene Therapy in Retinal Dystrophies
Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225722 · Cited by 107
Metadata
- Authors
- Kiang, A.-S., Palfi, A., Ader, M., Kenna, P. F., Millington-Ward, S., Clark, G., Kennan, A., O'Reilly, M., Tam, L. C. T., Aherne, A., McNally, N., Humphries, P., & Farrar, G. J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2005-09
- Volume
- 12
- Issue
- 3
- Pages
- 555-561
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2075929828
- Cited by
- 84
- References
- 3
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.